Why Old Muscle Still Hears the Growth Signal but Goes Deaf to the Repair Signal

Danish researchers stretched isolated leg muscles from young and old mice in a dish and watched which internal growth signals fired. The main growth-and-build pathway (mTORC1) responded just as strongly in old muscle as in young. But a second pathway that helps switch on muscle-remodeling genes (JNK feeding into SMAD2) was roughly cut in half in the old muscle. Because the muscles were tested outside the body, with no blood, nerves, or hormones involved, the result argues that a good chunk of the “anabolic resistance” seen in aging bodies is not baked into the muscle fiber itself. Instead it likely comes from the aging environment around the muscle. One repair-signaling pathway, though, does appear to weaken from the inside.

For decades the accepted story of muscle aging has been that old muscle simply stops listening to exercise. Load it, feed it protein, and it responds more weakly than young muscle. This blunted response, called anabolic resistance, is one of the mechanistic engines behind sarcopenia, the age-related loss of muscle mass and strength that erodes independence in later life. The open question has always been where the fault lies. Is the muscle fiber itself broken, or is the problem the aged body it lives in, with its poorer blood flow, altered hormones, and simmering low-grade inflammation?

A group at Aarhus University in Denmark went after that question by taking the body out of the equation. They isolated the extensor digitorum longus, a fast-twitch lower-leg muscle, from young adult mice (16 weeks) and old mice (24 months), then stretched each muscle mechanically in an oxygenated bath with no nerves, no circulation, and no hormones. Each animal donated one muscle for stretching and the opposite muscle as an untouched control, a clean within-animal comparison.

The headline result splits in two. The mTORC1 pathway, which controls the protein-building machinery, lit up just as strongly in old muscle as in young after stretch. The molecular readouts (mTOR, p70S6K, rpS6, 4E-BP1) rose to similar levels regardless of age. If old muscle were intrinsically deaf to mechanical load, this pathway should have been quieter. It was not.

The second pathway told a different story. JNK, a strain-sensitive kinase, and its downstream target SMAD2 at its linker region, drive the gene-level remodeling that lets muscle adapt. Here the old muscle responded at roughly half the magnitude of young muscle, and this age gap was statistically robust.

The interpretation is that aging does not flip one master switch. It selectively dampens the branch tied to turning genes on and off, while leaving the branch that builds protein largely intact. The practical implication is provocative. If translational signaling is preserved inside the fiber, then much of the anabolic resistance observed in living older people may be imposed from outside the muscle, by the systemic environment, rather than being an irreversible defect of the muscle itself. That is a more hopeful framing, because systemic factors are more modifiable than hardwired cellular decline.

Actionable Insights

Be careful here, because this is a mouse study done on muscles in a dish, not a human trial. It tests mechanism, not a supplement or a workout you can copy. That said, a few useful take-home messages emerge.

First, the growth-signaling machinery in aging muscle is not broken. Mechanical tension alone was enough to fully activate the main build pathway in old muscle. The practical translation is that resistance and stretch-loading exercise remains a legitimate anabolic stimulus into old age, and the “you are too old to build muscle” narrative is not supported at the level of the muscle fiber.

To put a number on the stimulus itself, stretching produced large signaling jumps. In old muscle the build-pathway markers rose roughly 1.7-fold (mTOR) up to 3.9-fold (p70S6K) over the unstretched control. Expressed as a standardized effect size, which measures how big a change is relative to its own variability, most of these responses land at a Cohen’s d well above 0.8, the conventional threshold for a large effect. In plain terms, the signal clearly rises above the noise.

Second, the aging deficit was specific to the remodeling pathway, which fell to about half of the young response (a roughly 45 to 51 percent reduction, effect size Cohen’s d near 1.0). This is where age genuinely bites at the cellular level.

Third, and most actionable at the whole-body level, the preserved internal machinery points the finger at systemic factors you can influence: circulating inflammation, protein and amino acid delivery, insulin sensitivity, and blood flow. Managing those may matter as much as the exercise itself.

Context and Source

  • Open Access Paper: Aging preserves mTORC1 but attenuates JNK-SMAD2L signaling sensitivity to passive stretch-induced tension development in isolated mouse skeletal muscle.
  • Institution and Country: Aarhus University, Aarhus, Denmark (Exercise Biology, Department of Public Health), with one co-author affiliated with NMD Pharma A/S, Aarhus, Denmark.
  • Journal: Experimental Gerontology (Elsevier).
  • Impact evaluation: The most recent metrics place the Journal Impact Factor around 5.1 (2025 release, June 2026) and the CiteScore at 6.7. Taking the impact factor: the impact score of this journal is 5.1, evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Low-to-Medium impact journal. Within its own specialist field of aging and gerontology it is a respectable, established mid-tier venue

Drugs or therapeutic interventions might potentially help maintain JNK response, and its downstream target SMAD2

The paper’s finding is that the acute, mechanically-triggered spike in JNK-SMAD2-L is blunted with age, not that baseline JNK is low. So the therapeutic goal is restoring the dynamic mechanosensitive response, not flogging the kinase. There is no clean “JNK agonist” in development, and the well-known JNK tool compounds (SP600125 and similar) are inhibitors, which would do the opposite.

With that framing, there are three realistic angles.

The physiological one, and the best-validated, is mechanical loading itself. The Lessard 2018 work that this pathway rests on showed the JNK to SMAD2-linker axis is switched on by resistance exercise but not endurance exercise in human muscle, and eccentric (lengthening) contractions are especially potent JNK activators. If any single intervention “maintains” this pathway, it is regular heavy or eccentric resistance training, which is also the stimulus the aged pathway is failing to respond to fully. Nothing pharmacological currently beats that as a JNK-SMAD2-L stimulus. [Confidence: High]

The pragmatic pharmacological route is to hit the downstream target rather than JNK. The entire purpose of SMAD2-linker phosphorylation is to relieve the myostatin/TGF-β brake on growth genes. You can relieve that same brake directly with myostatin/activin pathway blockers, bypassing the aged, unresponsive JNK step entirely. The clinical agents here are bimagrumab (an activin type II receptor antibody, roughly 6 to 8 percent lean mass gain in older adults), apitegromab and taldefgrobep alfa (selective myostatin inhibitors), and follistatin-based gene therapy approaches. Two important reality checks: in trials these reliably add muscle mass but produced modest and inconsistent gains in actual strength and function, and the field has largely pivoted to using them to preserve lean mass during GLP-1 (semaglutide, tirzepatide) weight loss rather than for sarcopenia per se. They do not restore mechanosensitivity; they route around it. [Confidence: High that they lower the myostatin brake, Medium on meaningful functional benefit in aging]

The mechanistically interesting but least-proven route is repairing the upstream sensing apparatus. The paper itself speculates the defect may sit in the force-transmission machinery, the costameres, integrin complexes, and extracellular matrix, and that the aged systemic milieu (chronic low-grade inflammation, TNF and IL-6) may be blunting the response. That points to anti-fibrotic and TGF-β modulation to reduce the stiffened, fibrotic aged ECM that impairs force transfer to the myofiber, and to controlling systemic inflammation so that tonic stress-kinase activation does not eat the pathway’s dynamic range. These are hypotheses, not validated targets.

The nutraceuticals people ask about in this space, epicatechin (small human data on raising follistatin and lowering myostatin), ursolic acid, HMB, plus adequate leucine-rich protein and vitamin D, act mainly on the myostatin/anabolic side and have weak, mostly non-clinical evidence. Reasonable as adjuncts, not as targeted JNK therapy.

One honest counterpoint on target validity: an older human study (Williamson 2004) found that aging did not alter the mechanosensitivity of JNK2 in skeletal muscle, which directly conflicts with this mouse paper. So the human relevance of a specifically “blunted JNK-SMAD2-L” target is still unsettled, which is another reason the direct myostatin-blockade route is currently the more defensible bet.

3 Likes